生命科学资讯

FDA wants to use more real-world data and calls again for early-phase trials reform

Enhertu combo wins FDA approval for first-line use in metastatic breast cancer

FDA speeds up review of J&J's multiple myeloma combo treatment following positive data

With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels

Gilead posts second Phase 3 win for new HIV-fighting drug regimen

Aviceda's geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?

Palvella unwraps Phase 2 data for rapamycin gel in rare skin disease

Areteia Therapeutics to wind down after terminating Phase 3 asthma studies

Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA

Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront

AI biotech Chai Discovery raises $130M Series B at $1.3B valuation

Western genetic medicine makers turn to Chinese investigator-initiated trials

Argenx cans thyroid eye disease trials of Vyvgart Hytrulo

Sobi to buy gout biotech Arthrosi for $950M upfront

Milestone finally wins FDA approval for arrythmia nasal spray

Eli Lilly’s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and more

340B sales grew 23% last year, and court battle over pilot program intensifies

Covid vaccine deaths review sent to top of FDA, but with far less certain conclusions, sources say

A 2-speed payer transformation is underway

CHMP calls to reject Anavex's Alzheimer’s pill over impurities, side effects and weak efficacy